VCEL Overview

Put Contract Overview: The $30.00 put contract has a bid of 25 cents, allowing investors to buy VCEL shares at a cost basis of $29.75, which is a 16% discount from the current price of $35.81. There is a 78% chance the contract may expire worthless, offering a potential 0.83% return on cash commitment.

Call Contract Overview: The $45.00 call contract has a bid of 10 cents, enabling investors to sell VCEL shares at that price, which represents a 26% premium over the current stock price. If the contract expires worthless, investors keep their shares and the premium, yielding a 0.28% extra return.

Volatility Insights: The implied volatility for the put contract is 74%, while the call contract has an implied volatility of 88%. The actual trailing twelve-month volatility is calculated at 49%.

YieldBoost Tracking: Stock Options Channel will monitor and publish the odds of both the put and call contracts expiring worthless over time, providing insights into potential returns and trading history for investors.

Company Announcement: Vericel Corporation will participate in a fireside chat at the Stephens Annual Investment Conference on November 20, 2025, at 11:00 a.m. ET, with a webcast available on their Investor Relations website.

Company Overview: Vericel is a leader in advanced therapies for sports medicine and severe burn care, offering innovative cell therapies and specialty biologics to repair injuries and restore lives.

Product Portfolio: The company markets three main products in the U.S.: MACI® for knee cartilage repair, Epicel for skin replacement in burn patients, and holds rights to NexoBrid for eschar removal in burn treatment.

Contact Information: For investor inquiries, Eric Burns can be reached via email at ir@vcel.com or by phone at +1 (734) 418-4411.

Vericel Corporation Overview: Vericel Corporation (NASDAQ: VCEL) is recognized as a promising small-cap stock, with Truist recently lowering its price target from $46 to $41 while maintaining a Buy rating, anticipating healthy Q3 revenue despite potential stock volatility.

Product Portfolio and Market Position: The company specializes in patient-specific cellular therapies, including products like Epicel for skin replacement and MACI for tissue engineering, although some analysts suggest that certain AI stocks may present better investment opportunities with less risk.